SABS

In the past six months (April 2026 - October 2026), SAB Biotherapeutics' stock experienced fluctuations, with a -20.4% 1-month change and a +23.5% 1-year change as of October 8, 2026, and a -23.90% change over the six-month period. Key events included the Q1 2026 earnings release on May 8, 2026, and the Q2 2026 financial results and business highlights reported on August 6, 2026. The company participated in investor conferences, with an announcement on September 1, 2026, and presented SAB-142 data at the 62nd Annual Meeting of the European Association for the Study of Diabetes on September 22, 2026, and at the Inaugural Breakthrough T1D Clinical & Research Congress on October 1, 2026. Additionally, the company participated in the Citi Biopharma Back to School Conference on September 10, 2026, and a tax withholding event trimming a CMO stake was reported on October 1, 2026.